Multiple Myeloma Expert Roundtable: Risk Assessment, Minimal Residual Disease, and Precision Medicine

Jointly provided by

Support for this activity has been provided through educational grants from Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Scroll to the Bottom of this Information to Begin this Course

Release date: December 27, 2017

Valid through: December 27, 2018

Specialty: Hematology/Oncology, Oncology

Topic: Multiple Myeloma

Media: Internet

Estimated Time to Complete Activity: 30 minutes

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.

Program Overview

The clinical multiple myeloma arena has undergone significant advancement in recent years; not only have 10 drugs been added to the armamentarium, but there have been important developments in diagnosis and staging, minimal residual disease (MRD) monitoring, and supportive care. The expansion of clinical options brings both opportunities and challenges for health care providers who see myeloma patients.

In this roundtable, our expert panel discusses the newest evidence regarding the identification and treatment of high-risk disease, MRD measurement and results interpretation, and the clinical implications of the latest precision medicine trial results. This activity includes downloadable resources (including supplemental figures and tables).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply the updated International Myeloma Working Group (IMWG) criteria, the Revised International Staging System (R-ISS), fluorescence in situ hybridization (FISH), and imaging to define patient diagnosis, prognosis, and risk stratification
  • Describe the benefits and limitations of the methods to detect MRD such as next-generation sequencing and multiparameter flow cytometry
  • Evaluate emerging evidence to better personalize therapy and offer more precise options to patients

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit

All other health care professionals completing this course will be issued a statement of participation.

Faculty

Sagar Lonial, MD, FACP

Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial completed his medical degree at the University of Louisville School of Medicine in Kentucky. He completed his internship and residency at Baylor College of Medicine in Houston, Texas; served as Chief Medical Resident at the Ben Taub General Hospital and the Texas Heart Institute at St. Luke’s Hospital; and completed a fellowship in hematology/oncology at Emory University School of Medicine.

Board certified in hematology and medical oncology, Dr. Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research. He is involved in numerous professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He is Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the board of directors for the International Myeloma Society and the scientific Advisory Board for the International Myeloma Foundation. He is also a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.

Dr. Lonial’s recent research has focused on combinations of novel agents as therapy for myeloma and lymphoma, and particularly on evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society. Dr. Lonial has authored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology and Leukemia; is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia; and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others.

Dr. Lonial’s research focuses on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell cancers, as well as methods to enhance immunity following allogeneic or autologous stem cell transplant.

Dr. Lonial is a member of several local committees as well as a member of several committees for the American Society of Hematology. He is also involved in numerous professional organizations including the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the American Journal of Clinical Oncology and as an invited or ad hoc reviewer for several publications, including Blood, Journal of Clinical Oncology, and Haematologica, Clinical Cancer Research, Leukemia, and others. Dr Lonial has authored or coauthored numerous publications and abstracts and has given several presentations, locally, nationally, and internationally.

A. Keith Stewart, MBChB, MRCP, FRCPC, MBA

Carlson and Nelson Endowed Director
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Scottsdale, Arizona

Keith Stewart earned his MBChB degree at Aberdeen University Medical School in the United Kingdom and an MBA degree at the University of Western Ontario. He completed an internship at Glasgow Royal Infirmary in Glasgow, United Kingdom; a residency in internal medicine at Queens University, Kingston, Ontario; a fellowship in hematology at the University of Toronto; and a fellowship in research at New England Medical Center in Boston.

Dr. Stewart is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine, at Mayo Clinic in Arizona. He currently serves as the Carlson and Nelson Endowed Director of the Center for Individualized Medicine and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart holds the academic rank of professor of medicine at the Mayo Clinic College of Medicine.

Dr. Stewart’s research focuses on the biology, genomics, and individualized treatment of multiple myeloma. He has over 20 years of sustained national funding for a laboratory research program in genomics and biology of myeloma and has led numerous clinical trials of new drugs for this blood cancer. He consistently publishes in high-impact scientific journals and holds editorial and reviewer responsibilities for several prominent publications. He is frequently invited to give presentations on his research both domestically and internationally and has authored over 300 journal articles, abstracts, and other written publications.

In recognition of his work, Dr. Stewart has received numerous awards and honors, including being named the Scott-Whitmore Chair in Hematology and Gene Therapy, conferred by the University of Toronto; one of Canada’s Top 40 Under 40; and one of America’s Top Doctors, conferred by Castle Connolly Medical Ltd.

In addition to his research activities, Dr. Stewart is active in education and mentoring. He holds full faculty privileges in molecular pharmacology and experimental therapeutics at Mayo Graduate School, Mayo Clinic College of Medicine. He has also served in several leadership roles across both research and practice at Mayo Clinic, including as dean for research in Arizona, chair of the Arizona Research Operations Management Team, and member of the Arizona Executive Operations Team and Clinical Practice Committees.

Jeffrey L. Wolf, MD

Clinical Professor of Medicine
Director, Multiple Myeloma Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Jeffrey L. Wolf earned a medical degree at the University of Illinois in Chicago and completed a residency in medicine at the University of California in San Diego. He completed a hematology and oncology fellowship at UCSF and a bone marrow transplantation rotation at the Fred Hutchinson Cancer Center in Seattle. He helped establish the bone marrow transplant program at the City of Hope National Medical Center in Duarte, California and then the first community hospital–based bone marrow transplant unit at Alta Bates Medical Center in Berkeley. Dr. Wolf joined the UCSF Division of Hematology and Oncology in 2007.

An expert in cancers of the bone marrow and blood, as well as in bone marrow transplantation to treat these cancers, Dr. Wolf focuses his clinical practice on multiple myeloma. He is the director of the Multiple Myeloma Program and the Grand Multiple Myeloma Translational Initiative (MMTI) at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Wolf has authored numerous articles in the peer-reviewed literature, and he is a frequent invited speaker. An active educator, Dr. Wolf lectures and mentors doctorate and medical students. His primary research interest is developing a myeloma program that incorporates basic science, clinical research, and a translational component. As part of the MMTI, he and his colleagues were able to re-direct eight world-class basic science labs into devoting some of their research specifically to myeloma. Among Dr. Wolf’s other notable contributions is assisting in expanding the imaging capabilities at an oncology hospital in Bhaktapur, Nepal—arranging for donations of essential diagnostic equipment.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine (PSCM), RedMedEd, and the Multiple Myeloma Research Foundation (MMRF). PSCM is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation

PSCM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Sagar Lonial, MD, FACP
  • Consultant/Advisor: Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Takeda
A. Keith Stewart, MBChB, MRCP, FRCPC, MBA
  • Consultant/Advisor: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Roche
Jeffrey L. Wolf, MD
  • Consultant/Advisor: Amgen, Celgene, Takeda
Penn State College of Medicine
  • Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
  • Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
RedMedEd
  • Denise C. LaTemple, PhD, Director of Scientific Services: no relevant financial relationships.
  • Kristen Petro Slade, Director of Operations: no relevant financial relationships.
  • Jonathan S. Simmons, ELS, Senior Managing Editor: no relevant financial relationships.
  • Karen Smith, Creative Director: no relevant financial relationships.
  • Karen Tenaglia, Project Manager: no relevant financial relationships.

Instructions for Participation and Credit

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.

For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6164-18-T.

Hardware and Software Requirements

This site is best viewed with an HTML5-compatible browser; this includes versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Safari. You can visit the independent (third party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PSCM, RedMedEd, the MMRF, Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PSCM, RedMedEd, the MMRF, Amgen, Celgene Corporation, or Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.